FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2792947977> ?p ?o ?g. }

• W2792947977 endingPage "A10" @default.
• W2792947977 startingPage "LB" @default.
• W2792947977 abstract "Abstract Background: HRAS is a proto-oncogene that is mutated in head and neck, bladder, thyroid, and salivary gland tumors, among others. While discovered over 40 years ago, no specific therapies have yet been developed targeting mutant HRAS. Tipifarnib is a potent and highly selective inhibitor of farnesyltransferase, a critical enzyme requisite for HRAS activation. Over 5,000 patients (pts) have been treated with tipifarnib; although responses have been documented in several tumor indications, the mechanisms of response are still poorly understood. Tipifarnib has demonstrated robust activity in HRAS mutant patient derived xenograft (PDX) models of head and neck squamous cell carcinoma (HNSCC) and squamous non-small cell lung cancer that are resistant to standard therapies. This Phase 2 study (NCT02383927) was conducted to test the hypothesis that inhibition of mutant HRAS oncogenic activity with tipifarnib could translate to objective responses in HNSCC pts driven by the HRAS oncogene. Methods: The study was originally designed to enroll pts into 2 single-arm study cohorts: Cohort 1 (thyroid cancer) and Cohort 2 (other solid tumors), each one with a 2-stage design (11+7 evaluable pts) to determine overall response rate (ORR) as the primary objective. This design has 80% power to detect a difference between 10% and 30% ORR at one-sided significance level of 0.087. Two objective responses were needed to be observed in the first stage for each cohort to proceed to stage 2. The study is considered positive if at least 4 responses are observed in one of the 2 cohorts (N=18 each, stages 1 and 2 combined). The prespecified activity goal for the first stage of accrual in Cohort 2 was met and based on data observed in the first stage of this Cohort, ongoing enrollment to the second stage of Cohort 2 was limited to HRAS mutant HNSCC. For enrollment, pts must have an HRAS mutant, locally advanced/unresectable and/or metastatic solid tumor malignancy and RECIST v1.1 measurable disease. Tipifarnib is given at 900 mg orally twice daily on days 1-7 and 15-21 of 28-day cycles. Response assessments are conducted every 8 weeks. Results: As of August 30, 2017, 28 pts have been enrolled. Tipifarnib was generally well tolerated with myelosuppression, gastrointestinal disturbances (nausea, vomiting and diarrhea) and fatigue constituting the most common adverse events (≥30% of pts, all grades). Twenty four pts are currently evaluable for efficacy: 10 in Cohort 1 and 14 in Cohort 2. Stage 1 enrollment continues in Cohort 1. The primary objective was met for Cohort 2 prior to completing full enrollment, with 4 confirmed responses observed out of 14 evaluable pts. Notably, of the 6 pts in Cohort 2 with HNSCC currently evaluable for efficacy, 4 (67%) achieved a confirmed partial response. Three of these pts remain on treatment in cycles 3, 5, and 19, and one subject discontinued at Cycle 21. Two (33%) pts had disease stabilization as best response (4 cycles, ongoing and 7 cycles). Importantly, 4 of these pts were refractory to prior therapies, including regimens containing immunotherapy (pembrolizumab, nivolumab) or cetuximab +/- chemotherapy. None of the 6 HNSCC patients experienced an objective partial response on their last prior therapy. Conclusions: These data suggest that HRAS mutant HNSCC pts may be refractory to standard therapies but can derive prolonged clinical benefit from tipifarnib treatment. Based on the encouraging activity of tipifarnib in pts with HNSCC with HRAS mutations, enrollment continues in this cohort. Citation Format: Alan Ho, Nicole Chau, Deborah J. Wong, Maria E. Cabanillas, Jessica Bauman, Marcia S. Brose, Keith Bible, Valentina Boni, Irene Brana, Charles Ferte, Caroline Even, Francis Burrows, Linda Kessler, Vishnu Mishra, Kelly Magnuson, Catherine Scholz, Antonio Gualberto. Preliminary results from a phase 2 proof of concept trial of tipifarnib in tumors with HRAS mutations [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-A10." @default.
• W2792947977 created "2018-03-29" @default.
• W2792947977 creator A5005127561 @default.
• W2792947977 creator A5009392187 @default.
• W2792947977 creator A5017176613 @default.
• W2792947977 creator A5020352800 @default.
• W2792947977 creator A5020600588 @default.
• W2792947977 creator A5021891844 @default.
• W2792947977 creator A5027112745 @default.
• W2792947977 creator A5036572642 @default.
• W2792947977 creator A5041365902 @default.
• W2792947977 creator A5058393482 @default.
• W2792947977 creator A5063754396 @default.
• W2792947977 creator A5070634393 @default.
• W2792947977 creator A5073636065 @default.
• W2792947977 creator A5079422406 @default.
• W2792947977 creator A5086245221 @default.
• W2792947977 creator A5087682958 @default.
• W2792947977 creator A5088573961 @default.
• W2792947977 date "2018-01-01" @default.
• W2792947977 modified "2023-09-26" @default.
• W2792947977 title "Abstract LB-A10: Preliminary results from a phase 2 proof of concept trial of tipifarnib in tumors with HRAS mutations" @default.
• W2792947977 doi "https://doi.org/10.1158/1535-7163.targ-17-lb-a10" @default.
• W2792947977 hasPublicationYear "2018" @default.
• W2792947977 type Work @default.
• W2792947977 sameAs 2792947977 @default.
• W2792947977 citedByCount "2" @default.
• W2792947977 countsByYear W27929479772018 @default.
• W2792947977 countsByYear W27929479772022 @default.
• W2792947977 crossrefType "journal-article" @default.
• W2792947977 hasAuthorship W2792947977A5005127561 @default.
• W2792947977 hasAuthorship W2792947977A5009392187 @default.
• W2792947977 hasAuthorship W2792947977A5017176613 @default.
• W2792947977 hasAuthorship W2792947977A5020352800 @default.
• W2792947977 hasAuthorship W2792947977A5020600588 @default.
• W2792947977 hasAuthorship W2792947977A5021891844 @default.
• W2792947977 hasAuthorship W2792947977A5027112745 @default.
• W2792947977 hasAuthorship W2792947977A5036572642 @default.
• W2792947977 hasAuthorship W2792947977A5041365902 @default.
• W2792947977 hasAuthorship W2792947977A5058393482 @default.
• W2792947977 hasAuthorship W2792947977A5063754396 @default.
• W2792947977 hasAuthorship W2792947977A5070634393 @default.
• W2792947977 hasAuthorship W2792947977A5073636065 @default.
• W2792947977 hasAuthorship W2792947977A5079422406 @default.
• W2792947977 hasAuthorship W2792947977A5086245221 @default.
• W2792947977 hasAuthorship W2792947977A5087682958 @default.
• W2792947977 hasAuthorship W2792947977A5088573961 @default.
• W2792947977 hasConcept C1167327 @default.
• W2792947977 hasConcept C121608353 @default.
• W2792947977 hasConcept C126322002 @default.
• W2792947977 hasConcept C143998085 @default.
• W2792947977 hasConcept C2776530083 @default.
• W2792947977 hasConcept C2776833033 @default.
• W2792947977 hasConcept C2781018059 @default.
• W2792947977 hasConcept C2781187634 @default.
• W2792947977 hasConcept C29537977 @default.
• W2792947977 hasConcept C502942594 @default.
• W2792947977 hasConcept C526805850 @default.
• W2792947977 hasConcept C71924100 @default.
• W2792947977 hasConcept C72563966 @default.
• W2792947977 hasConceptScore W2792947977C1167327 @default.
• W2792947977 hasConceptScore W2792947977C121608353 @default.
• W2792947977 hasConceptScore W2792947977C126322002 @default.
• W2792947977 hasConceptScore W2792947977C143998085 @default.
• W2792947977 hasConceptScore W2792947977C2776530083 @default.
• W2792947977 hasConceptScore W2792947977C2776833033 @default.
• W2792947977 hasConceptScore W2792947977C2781018059 @default.
• W2792947977 hasConceptScore W2792947977C2781187634 @default.
• W2792947977 hasConceptScore W2792947977C29537977 @default.
• W2792947977 hasConceptScore W2792947977C502942594 @default.
• W2792947977 hasConceptScore W2792947977C526805850 @default.
• W2792947977 hasConceptScore W2792947977C71924100 @default.
• W2792947977 hasConceptScore W2792947977C72563966 @default.
• W2792947977 hasIssue "1_Supplement" @default.
• W2792947977 hasLocation W27929479771 @default.
• W2792947977 hasOpenAccess W2792947977 @default.
• W2792947977 hasPrimaryLocation W27929479771 @default.
• W2792947977 hasRelatedWork W2037255674 @default.
• W2792947977 hasRelatedWork W2042520059 @default.
• W2792947977 hasRelatedWork W2167729693 @default.
• W2792947977 hasRelatedWork W2467622083 @default.
• W2792947977 hasRelatedWork W2792929645 @default.
• W2792947977 hasRelatedWork W2978998859 @default.
• W2792947977 hasRelatedWork W3126656898 @default.
• W2792947977 hasRelatedWork W3159483703 @default.
• W2792947977 hasRelatedWork W4362488203 @default.
• W2792947977 hasRelatedWork W4362488217 @default.
• W2792947977 hasVolume "17" @default.
• W2792947977 isParatext "false" @default.
• W2792947977 isRetracted "false" @default.
• W2792947977 magId "2792947977" @default.
• W2792947977 workType "article" @default.